Volume | 0 |
|
|||||
News | - |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Rocket Pharmaceuticals Inc | RCKTW | NASDAQ | Equity Warrant |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.07 |
Trades | Shares Traded | Average Volume |
---|---|---|
0 | 0 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | 0.07 | USD |
Rocket Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.31M | 90.16M | - | 0 | -245.6M | -2.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Rocket Pharmaceuticals
Date | Time | Source | Heading |
---|---|---|---|
6/10/2024 | 09:34 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of.. |
5/20/2024 | 15:36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
5/20/2024 | 15:33 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
5/20/2024 | 15:29 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
5/20/2024 | 15:26 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
5/16/2024 | 15:27 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
5/16/2024 | 14:44 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
5/16/2024 | 14:41 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
5/16/2024 | 14:41 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
5/06/2024 | 16:26 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
RCKTW Historical
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. |